دورية أكاديمية
أعرض في EDS

Innovative Strategies to Combat 5-Fluorouracil Resistance in Colorectal Cancer: The Role of Phytochemicals and Extracellular Vesicles.

التفاصيل البيبلوغرافية
العنوان: Innovative Strategies to Combat 5-Fluorouracil Resistance in Colorectal Cancer: The Role of Phytochemicals and Extracellular Vesicles.
المؤلفون: Barathan M; Centre for Tissue Engineering and Regenerative Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur 56000, Malaysia., Zulpa AK; Department of Medical Microbiology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia., Ng SL; Department of Craniofacial Diagnostics and Biosciences, Faculty of Dentistry, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, Kuala Lumpur 50300, Malaysia., Lokanathan Y; Centre for Tissue Engineering and Regenerative Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur 56000, Malaysia., Ng MH; Centre for Tissue Engineering and Regenerative Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur 56000, Malaysia., Law JX; Centre for Tissue Engineering and Regenerative Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur 56000, Malaysia.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2024 Jul 08; Vol. 25 (13). Date of Electronic Publication: 2024 Jul 08.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Fluorouracil*/pharmacology , Fluorouracil*/therapeutic use , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/metabolism , Extracellular Vesicles*/metabolism , Drug Resistance, Neoplasm*/drug effects , Phytochemicals*/therapeutic use , Phytochemicals*/pharmacology, Humans ; Tumor Microenvironment/drug effects ; Animals
مستخلص: Colorectal cancer (CRC) is a significant public health challenge, with 5-fluorouracil (5-FU) resistance being a major obstacle to effective treatment. Despite advancements, resistance to 5-FU remains formidable due to complex mechanisms such as alterations in drug transport, evasion of apoptosis, dysregulation of cell cycle dynamics, tumor microenvironment (TME) interactions, and extracellular vesicle (EV)-mediated resistance pathways. Traditional chemotherapy often results in high toxicity, highlighting the need for alternative approaches with better efficacy and safety. Phytochemicals (PCs) and EVs offer promising CRC therapeutic strategies. PCs, derived from natural sources, often exhibit lower toxicity and can target multiple pathways involved in cancer progression and drug resistance. EVs can facilitate targeted drug delivery, modulate the immune response, and interact with the TME to sensitize cancer cells to treatment. However, the potential of PCs and engineered EVs in overcoming 5-FU resistance and reshaping the immunosuppressive TME in CRC remains underexplored. Addressing this gap is crucial for identifying innovative therapies with enhanced efficacy and reduced toxicities. This review explores the multifaceted mechanisms of 5-FU resistance in CRC and evaluates the synergistic effects of combining PCs with 5-FU to improve treatment efficacy while minimizing adverse effects. Additionally, it investigates engineered EVs in overcoming 5-FU resistance by serving as drug delivery vehicles and modulating the TME. By synthesizing the current knowledge and addressing research gaps, this review enhances the academic understanding of 5-FU resistance in CRC, highlighting the potential of interdisciplinary approaches involving PCs and EVs for revolutionizing CRC therapy. Further research and clinical validation are essential for translating these findings into improved patient outcomes.
References: Front Immunol. 2018 Jun 28;9:1486. (PMID: 30002658)
Cancers (Basel). 2023 May 19;15(10):. (PMID: 37345176)
Int J Mol Sci. 2022 Jul 20;23(14):. (PMID: 35887332)
Lab Anim Res. 2014 Dec;30(4):143-50. (PMID: 25628724)
Biomolecules. 2023 Jan 18;13(2):. (PMID: 36830564)
Acta Pharm Sin B. 2024 Jan;14(1):133-154. (PMID: 38239235)
Cancer Lett. 2023 May 1;561:216151. (PMID: 37001751)
Med Res Rev. 1998 Sep;18(5):299-314. (PMID: 9735871)
Processes (Basel). 2021 Feb;9(2):. (PMID: 34336602)
Front Pharmacol. 2020 Sep 15;11:01021. (PMID: 33041781)
Cancer Sci. 2020 Sep;111(9):3142-3154. (PMID: 32536012)
Nutrients. 2021 May 24;13(6):. (PMID: 34073784)
Front Cell Dev Biol. 2022 Jun 24;10:816698. (PMID: 35813192)
Front Oncol. 2023 Jun 14;13:1194350. (PMID: 37388221)
Phytomedicine. 2021 Jan;81:153432. (PMID: 33310310)
Traffic. 2021 Jul;22(7):204-220. (PMID: 34053166)
Biomed Res Int. 2019 Dec 14;2019:3480569. (PMID: 31930117)
Biomedicines. 2018 Sep 09;6(3):. (PMID: 30205595)
Nat Commun. 2018 Nov 14;9(1):4783. (PMID: 30429478)
Cancer Prev Res (Phila). 2013 May;6(5):387-400. (PMID: 23466484)
J Biomed Sci. 2022 Feb 21;29(1):14. (PMID: 35189894)
J Oncol. 2022 Sep 13;2022:7099589. (PMID: 36147440)
Ther Adv Med Oncol. 2018 Jun 18;10:1758835918780140. (PMID: 29977352)
J Ethnopharmacol. 2020 Aug 10;258:112803. (PMID: 32251759)
Molecules. 2008 Aug 05;13(8):1551-69. (PMID: 18794772)
Integr Cancer Ther. 2019 Jan-Dec;18:1534735419828824. (PMID: 30791729)
J Cell Biochem. 2008 Jul 1;104(4):1124-49. (PMID: 18459149)
Sci Rep. 2020 May 19;10(1):8271. (PMID: 32427870)
Int J Mol Sci. 2021 Oct 28;22(21):. (PMID: 34769099)
Front Bioeng Biotechnol. 2023 Sep 26;11:1254356. (PMID: 37823027)
Clin Transl Oncol. 2023 Jul;25(7):2056-2068. (PMID: 36808392)
Cell Biochem Funct. 2022 Jun;40(4):391-402. (PMID: 35474580)
Int J Mol Sci. 2023 Jan 29;24(3):. (PMID: 36768876)
Oncol Res. 2017 May 24;25(5):651-661. (PMID: 27712599)
Front Cell Dev Biol. 2021 Sep 20;9:734720. (PMID: 34616741)
World J Gastroenterol. 2015 Nov 21;21(43):12234-48. (PMID: 26604633)
Cancers (Basel). 2020 May 14;12(5):. (PMID: 32422889)
Int J Mol Sci. 2021 Jul 19;22(14):. (PMID: 34299337)
Oncotarget. 2017 Sep 6;8(47):82842-82853. (PMID: 29137307)
World J Gastroenterol. 2014 Aug 7;20(29):9744-58. (PMID: 25110412)
Front Immunol. 2020 Dec 03;11:583084. (PMID: 33365025)
Molecules. 2015 Nov 27;20(12):21138-56. (PMID: 26633317)
J Cancer. 2020 Oct 18;11(24):7116-7126. (PMID: 33193874)
iScience. 2024 Feb 27;27(4):109350. (PMID: 38500820)
J Zhejiang Univ Sci B. 2009 Feb;10(2):93-102. (PMID: 19235267)
Gut. 2004 Nov;53(11):1701-9. (PMID: 15479695)
Mol Cancer. 2022 Jul 14;21(1):144. (PMID: 35836256)
Pharmaceutics. 2023 Jan 21;15(2):. (PMID: 36839686)
J Adv Res. 2024 Jan 6;:. (PMID: 38190940)
MedComm (2020). 2024 Apr 07;5(4):e541. (PMID: 38585234)
Anticancer Res. 2003 Jan-Feb;23(1A):363-98. (PMID: 12680238)
Biomed Pharmacother. 2016 Dec;84:780-788. (PMID: 27721176)
J Nutr. 2019 Jul 1;149(7):1133-1139. (PMID: 31132111)
Molecules. 2008 Oct 01;13(10):2340-69. (PMID: 18830159)
Oncol Lett. 2016 Oct;12(4):2840-2845. (PMID: 27698868)
Biomol Ther (Seoul). 2022 Nov 1;30(6):479-489. (PMID: 35440517)
Oncol Res. 2023 Nov 15;32(1):61-71. (PMID: 38188683)
Int J Oncol. 2022 Feb;60(2):. (PMID: 35014676)
Int J Mol Sci. 2022 Nov 14;23(22):. (PMID: 36430537)
BMC Cancer. 2024 Jan 12;24(1):64. (PMID: 38216964)
J Nanobiotechnology. 2023 Apr 29;21(1):143. (PMID: 37120534)
Biomed Pharmacother. 2023 Jun;162:114615. (PMID: 37011484)
Biomed Pharmacother. 2017 Mar;87:527-538. (PMID: 28076833)
Cancer Lett. 2017 May 1;393:94-102. (PMID: 28202351)
Front Oncol. 2023 Jul 19;13:1208140. (PMID: 37538108)
Cancer Sci. 2023 Jun;114(6):2293-2305. (PMID: 36788743)
Cancers (Basel). 2021 Feb 17;13(4):. (PMID: 33671415)
J Exp Clin Cancer Res. 2021 Jan 7;40(1):21. (PMID: 33413536)
Proc Natl Acad Sci U S A. 2021 Jan 19;118(3):. (PMID: 33431671)
Ther Adv Med Oncol. 2016 Jan;8(1):57-84. (PMID: 26753006)
BMC Cancer. 2021 Aug 19;21(1):933. (PMID: 34412616)
Prz Gastroenterol. 2019;14(2):89-103. (PMID: 31616522)
Oncotarget. 2017 Apr 18;8(31):51907-51919. (PMID: 28881699)
Oncotarget. 2020 Aug 04;11(31):2959-2972. (PMID: 32821342)
Cell Commun Signal. 2021 Apr 23;19(1):47. (PMID: 33892745)
Mol Cancer. 2019 May 7;18(1):91. (PMID: 31064356)
Molecules. 2017 Jun 18;22(6):. (PMID: 28629161)
World J Gastrointest Oncol. 2021 Sep 15;13(9):1043-1061. (PMID: 34616511)
Int J Mol Sci. 2022 Sep 14;23(18):. (PMID: 36142616)
Cell Signal. 2023 Sep;109:110737. (PMID: 37263461)
Int J Mol Sci. 2017 Jul 21;18(7):. (PMID: 28754000)
Mol Ther. 2013 Jul;21(7):1345-57. (PMID: 23752315)
Integr Med Res. 2014 Mar;3(1):16-24. (PMID: 28664074)
Biology (Basel). 2019 Sep 24;8(4):. (PMID: 31554173)
Springerplus. 2016 Aug 11;5(1):1318. (PMID: 27563513)
Cancer Metastasis Rev. 2010 Sep;29(3):465-82. (PMID: 20730632)
Cell Death Dis. 2022 Jan 13;13(1):57. (PMID: 35027547)
J Nat Prod. 2004 Feb;67(2):129-35. (PMID: 14987046)
Eur J Cell Biol. 2022 Jun-Aug;101(3):151226. (PMID: 35460959)
Stem Cell Res Ther. 2022 Apr 1;13(1):138. (PMID: 35365226)
Cancers (Basel). 2023 Feb 18;15(4):. (PMID: 36831648)
Oncol Lett. 2018 May;15(5):8019-8026. (PMID: 29849804)
J Oncol. 2021 Nov 9;2021:9355555. (PMID: 34795760)
Acta Pharm Sin B. 2022 Mar;12(3):1163-1185. (PMID: 35530162)
Biochem Biophys Res Commun. 2023 Jan 22;641:177-185. (PMID: 36535076)
Adv Biol Regul. 2018 May;68:46-54. (PMID: 29449169)
Mol Pharm. 2024 Jun 3;21(6):2625-2636. (PMID: 38771015)
Molecules. 2020 Jul 21;25(14):. (PMID: 32708169)
Front Pharmacol. 2022 Jan 24;13:820969. (PMID: 35140617)
Nanomedicine. 2016 Apr;12(3):655-664. (PMID: 26586551)
Cancers (Basel). 2022 Mar 08;14(6):. (PMID: 35326517)
Oncotarget. 2015 Feb 20;6(5):3225-39. (PMID: 25605009)
Swiss Med Wkly. 2021 Feb 15;151:w20390. (PMID: 33631027)
Curr Drug Metab. 2008 Sep;9(7):581-91. (PMID: 18781909)
Molecules. 2021 Feb 08;26(4):. (PMID: 33567547)
NAR Cancer. 2021 Aug 14;3(3):zcab032. (PMID: 34409299)
Phytomedicine. 2023 Feb;110:154608. (PMID: 36586205)
Gut. 2020 Nov 10;:. (PMID: 33172926)
BMC Cancer. 2017 Dec 04;17(1):813. (PMID: 29202800)
PLoS One. 2014 Jan 03;9(1):e85397. (PMID: 24404205)
Front Pharmacol. 2020 Jun 17;11:904. (PMID: 32625096)
ACS Omega. 2022 Feb 09;7(7):6046-6052. (PMID: 35224365)
Oxid Med Cell Longev. 2021 Jul 19;2021:3268136. (PMID: 34336089)
Mol Nutr Food Res. 2008 Jun;52 Suppl 1:S103-27. (PMID: 18496811)
Gastroenterol Rep (Oxf). 2014 Feb;2(1):1-15. (PMID: 24760231)
Biomed Pharmacother. 2023 Oct;166:115425. (PMID: 37660643)
Bull Cancer. 2018 Apr;105(4):336-349. (PMID: 29496262)
Pharmaceutics. 2024 May 24;16(6):. (PMID: 38931833)
Cancers (Basel). 2023 Mar 22;15(6):. (PMID: 36980785)
Annu Rev Pathol. 2023 Jan 24;18:205-229. (PMID: 36202098)
Cell Signal. 2021 Aug;84:110029. (PMID: 33932496)
Front Immunol. 2023 May 10;14:1161628. (PMID: 37234178)
Mol Ther. 2016 Oct;24(10):1783-1796. (PMID: 27491931)
J Exp Clin Cancer Res. 2021 Apr 15;40(1):132. (PMID: 33858476)
Int J Nanomedicine. 2023 Sep 05;18:4987-5009. (PMID: 37693885)
Int J Mol Sci. 2022 Nov 24;23(23):. (PMID: 36499000)
Cancer Biol Ther. 2008 Aug;7(8):1305-12. (PMID: 18497562)
World J Gastroenterol. 2023 Feb 28;29(8):1289-1303. (PMID: 36925459)
World J Gastrointest Oncol. 2016 Sep 15;8(9):642-55. (PMID: 27672422)
Molecules. 2021 Mar 11;26(6):. (PMID: 33799765)
Nanotheranostics. 2022 Jun 21;6(4):365-375. (PMID: 35795340)
J Control Release. 2021 Jun 10;334:164-177. (PMID: 33895200)
Cancers (Basel). 2021 Aug 28;13(17):. (PMID: 34503172)
Int J Nanomedicine. 2023 Aug 22;18:4779-4804. (PMID: 37635909)
Cancer Cell Int. 2021 Oct 18;21(1):547. (PMID: 34663329)
Proteomics. 2021 Jul;21(13-14):e2000118. (PMID: 33857352)
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231171463. (PMID: 37122245)
Mol Ther. 2019 Mar 06;27(3):493-506. (PMID: 30713087)
J Exp Clin Cancer Res. 2019 Jul 19;38(1):320. (PMID: 31324203)
Oncotarget. 2016 Mar 29;7(13):16158-71. (PMID: 26930714)
Cancers (Basel). 2022 Mar 29;14(7):. (PMID: 35406504)
Dis Model Mech. 2017 Mar 1;10(3):197-214. (PMID: 28250048)
Sci Rep. 2023 Sep 1;13(1):14359. (PMID: 37658132)
J Clin Invest. 2016 Apr 1;126(4):1152-62. (PMID: 27035807)
Pharmaceuticals (Basel). 2023 Jul 31;16(8):. (PMID: 37631000)
Cancer Sci. 2019 Aug;110(8):2396-2407. (PMID: 31148360)
APL Bioeng. 2019 Mar 27;3(1):011503. (PMID: 31069333)
World J Clin Oncol. 2021 Jul 24;12(7):522-543. (PMID: 34367926)
Cancer Lett. 2015 Aug 10;364(2):135-41. (PMID: 25979230)
Cell Death Dis. 2020 Jun 24;11(6):477. (PMID: 32581212)
J Vis Exp. 2019 Dec 19;(154):. (PMID: 31904021)
Oncol Rep. 2014 Aug;32(2):821-8. (PMID: 24890449)
Front Oncol. 2022 Apr 22;12:881641. (PMID: 35530318)
Front Immunol. 2022 Sep 02;13:972345. (PMID: 36159787)
Front Oncol. 2022 Jun 23;12:891652. (PMID: 35814435)
Front Cell Dev Biol. 2021 Oct 01;9:733270. (PMID: 34660589)
Pharmaceutics. 2023 Aug 01;15(8):. (PMID: 37631284)
Trends Mol Med. 2019 May;25(5):382-394. (PMID: 30853173)
Front Oncol. 2021 Nov 25;11:753598. (PMID: 34900704)
Exp Mol Med. 2018 Aug 14;50(8):1-12. (PMID: 30111797)
Curr Pharm Des. 2018;24(39):4626-4638. (PMID: 30636578)
Int J Mol Sci. 2019 Jul 09;20(13):. (PMID: 31324056)
Transl Cancer Res. 2021 May;10(5):2437-2450. (PMID: 35116559)
Carcinogenesis. 2021 Oct 5;42(9):1143-1153. (PMID: 34170291)
Biomed Pharmacother. 2019 Feb;110:473-481. (PMID: 30530050)
Front Pharmacol. 2019 Dec 06;10:1336. (PMID: 31866857)
J Neuroimmune Pharmacol. 2020 Sep;15(3):422-442. (PMID: 31456107)
World J Gastrointest Oncol. 2021 Dec 15;13(12):1981-1996. (PMID: 35070036)
Pathol Res Pract. 2022 Sep;237:154024. (PMID: 35905664)
Clin Immunol. 2021 Nov;232:108875. (PMID: 34740843)
Adv Nutr. 2015 Jul 15;6(4):408-19. (PMID: 26178025)
J Clin Med. 2023 Jun 07;12(12):. (PMID: 37373600)
Stem Cells. 2000;18(3):166-75. (PMID: 10840069)
Chemotherapy. 2006;52(1):23-8. (PMID: 16340194)
Molecules. 2021 Aug 02;26(15):. (PMID: 34361836)
معلومات مُعتمدة: DIP-2023-011 National University of Malaysia; FF-2022-330/1 National University of Malaysia
فهرسة مساهمة: Keywords: 5-fluorouracil resistance; colorectal cancer; drug transport; extracellular vesicles; phytochemicals
المشرفين على المادة: U3P01618RT (Fluorouracil)
0 (Phytochemicals)
تواريخ الأحداث: Date Created: 20240713 Date Completed: 20240713 Latest Revision: 20240715
رمز التحديث: 20240715
مُعرف محوري في PubMed: PMC11242358
DOI: 10.3390/ijms25137470
PMID: 39000577
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms25137470